China-based diagnostics firm Burning Rock has partnered with Illumina, to develop advanced clinical applications for molecular diagnostics in oncology.
Under the deal, Burning Rock will offer its nucleic acid extraction, library preparation and data analysis software, while Illumina will provide next-generation sequencing (NGS) components and related reagents.
Specifically, both companies will work together to develop a user-friendly, oncology molecular diagnostic kit for the Chinese market.
Burning Rock founder and CEO Yusheng Han said: "We have been working to promote the clinical application of genomic technology in China. Oncology molecular diagnosis based on NGS, including non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals."
Illumina senior vice-president and chief medical officer Dr Rick Klausner said: "We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome."
Burning Rock also has a molecular and pathological examination platform, comprising NGS, qPCR, IHC, FISH and digital pathology.
Illumina provides DNA sequencing and array-based technologies for customers in the research, clinical and applied markets.